A business that is on course to transform the food allergy diagnostics market has secured £2.9m investment in a funding round led by Praetura Ventures with follow-on equity investment from the Development Bank of Wales.  Reacta Biotech (Reacta), which is based in Deeside, North Wales, produces clinical diagnostics kits for food allergy testing. The business improves the efficiency, accuracy and safety of food allergy testing by producing pharmaceutical grade Oral Food Challenges (OFCs), the gold standard test for diagnosing food allergies.

Livingbridge has announced its investment in AJM Healthcare, the leading provider of NHS wheelchair services in England.  AJM provides services for over 100,000 wheelchair users across 13 locations.  It delivers a high quality, clinically led service focused on meeting the diverse needs of users.  AJM draws on the deep experience of its more than 270 staff to ensure leading outcomes and best-in-class service for both commissioners and service users.

IW Capital has made an investment in e-pharmacy company SimplyMeds, marking the first external investment in the highly scalable online platform.

SimplyMeds is an end-to-end digital pharmacy platform that provides a convenient method of ordering same day prescriptions and lifestyle products while empowering patients to have medical autonomy. While most online pharmacies are designed to service only one sector, SimplyMeds caters to both the private and NHS prescriptions market in what is believed to be a market first, having developed the distribution channels and a highly sophisticated platform to effectively serve both sectors. 

Pharmaceutical business Remedi Pharmacy Solutions has secured a £250,000 loan to support the development of its latest software platform and enable it to create seven new jobs.

Kuano.ai, a software platform for rapid, cost effective quantum modelling of enzymes, has raised £1 million in seed funding from ACF Investors, o2h Ventures and a syndicate of Cambridge-based angel investors. The funding will accelerate the company’s growth as it moves further towards commercialisation.

Foresight Group, the award-winning listed private equity and infrastructure investment manager, has announced a £1.5m follow-on investment into portfolio company Biotherapy Services Ltd, a leading pharmaceutical biotech company.  The funds will be used to support the clinical development of RAPID^TM Biodynamic Haematogel, currently in phase 2b/3 clinical trials in the treatment of DFUs.

QV Bioelectronics – a medical device start-up pioneering a first of its kind electric field therapy implant for the treatment of the most common and aggressive type of brain tumours, has closed a £735,000 seed funding round to advance the development of its innovative GRACE implant.

MediSieve Ltd, a biotech company which has developed an innovative blood filtration device, has completed a £1.8m investment, led by 24Haymarket.

Thymia has raised a £780k/$1.1m pre-seed round to scale its platform to assess for and monitor depression. The Thymia technology removes the subjectivity from mental health assessments: instead of answering questionnaires, patients play specially designed video games which use cutting-edge Neuropsychology, Linguistics and Machine Learning to detect signs of depression, as well as monitor whether symptoms are improving or worsening over time. 

Turquoise, the UK merchant bank specialising in energy, environment and efficiency, has invested in Ablatus Therapeutics for the Low Carbon Innovation Fund 2 (LCIF2). The investment of £85,000 is part of an overall round which could reach £1.5 million.

Ablatus Therapeutics is developing Bimodal Electric Tissue Ablation (BETA), an innovative improvement over existing tissue ablation techniques, in order to offer greater clinical options and to improve patient outcomes. 

Epipole, the video retinal imaging specialist, has started work on a €1.1 million collaborative project to develop a technology solution for the diagnosis of intracranial pressure (ICP). The project is funded by the Eureka Eurostars programme, and is a collaboration between Epipole, Denmark’s Statumanu ICP and the University of Southern Denmark.

Foresight Group has invested 3 million of growth capital into NorthWest EHealth Limited, providers of software and services to the clinical trials market.